Guest Editorial Why CAR-T policymaking is broken, and why we need to fix it September 13, 2019Vol.45 No.34By Michael Kolodziej, Louis Jacques and Marc Samuels
FreeGuest Editorial Learning from suramin: A case study of NCI’s much-hyped cancer drug that crashed and burned—35 years ago August 09, 2019Vol.45 No.32By Cy Stein
Guest Editorial The cost of underfunding research and the lingering dread of unstable funding July 26, 2019Vol.45 No.30By Candace S. Johnson
Guest Editorial Community oncology at a glance;How we got here and where we are going July 19, 2019Vol.45 No.29By Michael Kolodziej
Guest Editorial It’s time to rethink peer review policies—and consider an “Earth Shot Program” July 05, 2019Vol.45 No.27By Wafik S. El-Deiry
Guest Editorial Big Data for outcomes and clinical research:major advance or improvement needed June 07, 2019Vol.45 No.23By Roy B. Jones, Amar Chahal, Dianne Reeves, Gregory H. Jones and Charles S. Martinez
Guest Editorial Getting beyond the immunotherapy divide: a call to action May 03, 2019Vol.45 No.18By John H. Stewart and Robert A. Winn
Guest Editorial Congress must commit to sustained increases for NCI March 29, 2019Vol.45 No.13By Brian Higgins and Peter King
FreeGuest Editorial NCCN validates path toward de-escalated doses and reduced costs of cancer drugs March 29, 2019Vol.45 No.13By Allen S. Lichter, Mark J. Ratain, Leonard B. Saltz, Michael Stebbins and David Hyman
